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Abstract
Background: Our aim was to determinate bone mineral density (BMD), levels of biochemical
markers and cytokines in children with chronic hepatitis B treated with interferon (IFN)-alpha and
to investigate effect of IFN-alpha therapy on these variables. To the best of our knowledge, this is
first study carried out about BMD and cytokine levels in pediatric patients with chronic hepatitis B
treated with IFN-alpha.
Methods:  BMD, levels of parathyroid hormone (PTH), osteocalcin, C-terminal cross-linking
telopeptide of type I collagen (CTX), calcium, alkaline phosphates (ALP), cytokines as TNF-alpha,
interleukin (IL)-1β, IL-2r, IL-6, and IL-8 were studied in 54 children with chronic hepatitis B (4–15
years old) treated with interferon alone (n = 19) or in combination with lamivudine (n = 35) for six
months and as controls in 50 age-matched healthy children.
Results: There was no significant difference in respect to serum IL-1β, TNF-α and osteocalcin
levels while serum IL-2r (p = 0.002), IL-6 (p = 0.001), IL-8 (p = 0.013), PTH (p = 0.029), and CTX
(p = 0.021) levels were higher in children with chronic hepatitis B than in healthy controls. BMD of
femur neck (p = 0.012) and trochanter (p = 0.046) in patients were higher than in healthy controls.
There was a statistically significant correlation between serum IL-1β and osteocalcin (r = -0.355, p
< 0.01); between serum IL-8 and CTX levels (r = 0.372, p = 0.01), and ALP (r = 0.361, p = 0.01);
between serum ALP and femur neck BMD (r = 0.303, p = 0.05), and trochanter BMD (r = 0.365,
p = 0.01); between spine BMD and IL-2R (r = -0.330, p < 0.05).
Conclusion: In conclusion, our study suggest that BMD of femur, serum IL-2r, IL-6, IL-8, PTH, and
CTX levels were higher in children with chronic hepatitis B treated with IFN-alpha alone or
combination with lamivudine than in healthy children. High femur BMD measurements found in
patients may suggest that IFN-alpha therapy in children with chronic hepatitis B could contribute
indirectly to prevent from hip osteoporosis. Additionally, further investigations on effects of IFN-
alpha for bone structure in children should be performed in the future.
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Background
Bone development during childhood and adolescence is a
key determinant of adult skeleton health. A reduced bone
mass is associated with increased fracture risk in adults as
well as in children. Peak bone mass, which is reached by
early adulthood, serves as a bone reserve for the remain-
der of life, therefore childhood and adolescence are cru-
cial periods for bone development. Strategies
implemented for optimization of bone acquisition, as
well as factors adversely affecting bone growth during
these susceptible periods can have potentially long-stand-
ing consequences [1].
Recent studies have reported that osteodystrophy occurs
not only in patients with alcoholic cirrhosis, but also in
those with cirrhosis induced by hepatitis B and C viruses
[2,3]. Because of improved treatment, patients with cir-
rhosis are living longer, an increasing proportion of such
patients are found to have bone disease [4].
It is postulated that chronic liver disease and its complica-
tions might be responsible for activating some mediators
[5,6]. It is further postulated that these mediators, such as
some cytokines, might be the final common pathway
leading to bone loss in parenchimal liver disorders [7].
A variety of compounds, including hormones and nutri-
ents, are known to modulate bone remodelling. In addi-
tion, to these well-characterized substances, the immune
system plays a role in this process through the involve-
ment of pro-inflammatory cytokines [8]. Much interest
has been focused on the role of the immune system in
bone remodeling, and in particular, on the potential
influence of cytokines upon the autocrine and paracrine
regulation of bone cell activity [9-12]. Cytokines possess
an important role in the regulation of bone resorption
and formation during pathologic bone remodeling, and
they also play a role during normal bone remodeling [13].
Significantly, IL-6 is a potent activator of ostoclasts and
bone resorption. Similarly, other cytokines, such as IL-1,
IL-11 and TNF influence ostoclast function and the age
associated dysregulation of these cytokines may also con-
tribute to the development of osteoporotic bone disease
[8]. IL-8 is a chemokine of importance in inflammatory
processes, and causes an increase in the levels of parathy-
roid hormone (PTH) mRNA. This suggest that IL-8 and
inflammatory events may play a role in bone homeostasis
by acting upon the parathyroid gland [14-16].
Interferon (IFN) has been shown to be effective in induc-
ing inhibition of viral replication, normalization of liver
tests and even improvement of liver histology in HBV-
related liver diseases and it is known that IFN-alpha may
affect bone turnover. There is limited information about
the long-term effect of IFN-alpha therapy on bone
metabolism.
A large number of studies on hepatic osteodystrophy in
adult have reported recent advances in research on bone
metabolism. However, bone metabolism in children has
been regarded as differential diagnosis of bone resorption,
pathological mechanisms and effects of IFN-alpha has not
been elucidated.
Our aim was to determinate bone mineral density (BMD),
levels of biochemical markers and cytokine in children
with chronic hepatitis B treated with IFN-alpha and to
investigate effect of IFN-alpha therapy on these variables.
To the best of our knowledge, this is first study carried out
about BMD and cytokine levels in pediatric patients with
chronic hepatitis B treated with IFN-alpha. In view of the
cost and widespread universal use of this drug in all age
groups, especially with the epidemic of hepatitis B and C,
we feel that such a detailed study is important.
Methods
BMD, levels of PTH, osteocalcin, CTX, calcium, cytokines
as TNF-alpha, interleukin (IL)-1β, IL-2r, IL-6, and IL-8
were studied in 54 children with chronic hepatitis B (4–15
years old) treated with interferon alone (n = 19) or in
combination with lamivudine (n = 35) for six months and
as controls in 50 sex and age-matched healthy children.
This study was performed in Dicle University, Diyarbakir,
Turkey. Informed consent was taken from the parents of
patients and sufficient information was given to them
about the disease course and the treatment procedure at
the beginning of the study. The study was approved by the
local ethics committee.
BMD of the spine and hip (neck, trochanter) were meas-
ured by dual-energy x-ray absorptiometry (DEXA) (NOR-
LAND, 6938CE, New York, USA). The variation
coefficient for consecutive determinations on spine and
femur images in our laboratory was 1.9% at the lumbar
spine and 1.6 % at the femur region. All spinal scans were
reviewed for evidence of vertebrae with collapse or focal
sclerosis by an experienced radiologist.
The diagnostic criteria for chronic HBV infection were
seropositivity for hepatitis B surface antigen (HBsAg), lack
of anti-hepatitis B surface antibodies (anti-HBs), and pres-
ence of anticore IgG antibodies (anti-HBc). All patients
had been infected with HBV for more than 2 yr. The mean
time from the presumed onset of HBV infection, defined
as at least from the first documented elevation of serum
liver enzyme levels, to the study was 3.9 ± 3.2 yr. Knodell's
histological activity index was used to evaluate necro-
inflammation and fibrosis in biopsy samples from allBMC Gastroenterology 2005, 5:30 http://www.biomedcentral.com/1471-230X/5/30
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patients. Mean inflammatory score was 5.1 ± 2.4, and the
mean fibrosis score, 1.2 ± 1.1. None of all patients had
cirrhosis.
The diagnosis of all patients was confirmed after a thor-
ough laboratory investigation for their symptoms of
icterus, abdominal pain, fatigue and loss of appetite.
Moreover, family members of patients were tested for
serologic parameters of HBV in order to determine possi-
ble vertical or horizontal transmission.
Patients were excluded from the study, after the screening,
if they were more than 16 years old; if they had having
positive test results for antibody to hepatitis D virus, hep-
atitis C virus, or human immunodeficiency virus; having
decompensate liver disease (defined by a serum bilirubin
level more than 2.5 times the upper limit of normal, a pro-
thrombin time prolonged by more than 3 s and a serum
albumin level lower than 3 g/dl or a history of ascites,
variceal hemorrhage, or hepatic encephalopathy); if they
have evidence of autoimmune hepatitis (defined as an
anti-nuclear antibody titer higher than 1/160) or meta-
bolic liver disease (Wilson's disease, hemochromatosis,
deficit of α-1 antitrypsin); if they had received investiga-
tional drug within 30 days before enrollment. Patients
were also excluded if they had a total white-blood-cell
count less than 2500/m3, a neutrophil granulocyte count
less than 1000/mm3 and a value of haemoglobin less than
10 g/dl; if they were in poor clinical condition and/or had
serious medical diseases (e.g. malnutrition, cardiomyopa-
thies, diabetes, hypertension, neurologic, metabolic,
autoimmune and neoplastic diseases).
19 patients with hepatitis B who entered the study
received ten million units/ body surface area (max 10 mil-
lion units) three times per week of recombinant inter-
feron alpha 2b alone and 35 patients received interferon
alpha 2b in same dosage in combination with lamivudine
4 mg/kg (max 100 mg) for six months. Recombinant
interferon alpha-2b was administered subcutaneously by
qualified medical staff or by the parents of patients after
adequate training.
Blood samples were obtained after an over-night fast; pre-
cautions were taken to avoid contamination. Freshly
drawn blood (15 ml) samples were obtained and imme-
diately centrifuged at 200 × g (20 min at 24°C). For these
tests HBV antigens and antibodies were assessed by qual-
itative micro-particle enzyme immunoassay (Organon
Teknika BV, Boxtel, The Netherlands) HBV-DNA by
Digene Hybride Capture Systems (Beltsville, MD 20705,
USA). Serum levels of cytokines were determined using
IMMULITE diagnostic kits (DPC-Diagnostic Products
Corporation, USA). This diagnostic kit is an in vitro
enzyme-linked immunosorbent assay for the quantitative
measurement of human cytokines in serum. The serum
Osteocalcin level was measured with a commercially
available N-MID Osteocalcin Electrochemiluminescence
Immunoassay kit (Roche Diagnostics GmbH, Mannheim,
Germany). The serum levels of CTX were determined by
Elecsys β-Crosslaps commercially available immunoassay
kit (Roche Diagnostics GmbH, Mannheim, Germany).
Serum PTH was measured by a two-site immunoradio-
metric assay using a commercially available kit (Nichols
Institute). Serum and urinary chemical estimations were
performed using Beckman-Synchron CX-5 technology.
Statistical analysis
The data obtained were analyzed using the Statistical
Package for the Social Sciences (SPSS 10.0). Results in
Table 1: Comparisons of clinical features in patients with chronic hepatitis B treated with IFN alone or IFN plus lamivudine
Variables IFN-alpha (n = 19) IFN plus Lamivudine (n = 35) P
TNF-α 24.48 ± 8.46 26.60 ± 7.43 NS
IL-1β 7.56 ± 10.86 7.08 ± 12.47 NS
IL-2r 1472.42480.47 1333.72 ± 472.51 NS
IL-6 24.85 ± 31.46 25.57 ± 29.43 NS
IL-8 18.19 ± 13.88 18.73 ± 14.27 NS
PTH 42.03 ± 29.41 40.99 ± 26.92 NS
s-CTX 1.88 ± 0.68 1.96 ± 0.75 NS
Osteocalcin 65.49 ± 34.45 63.85 ± 32.67 NS
Serum calcium 9.28 ± 1.76 9.86 ± 1.69 NS
ALP 249.45 ± 71.34 193.09 ± 72.88 NS
ALT 62.83 ± 76.39 61.45 ± 81.54 NS
AST 59.16 ± 61.48 57.66 ± 59.82 NS
L2–4 BMD 0.63 ± 0.09 0.61 ± 0.14 NS
Femur neck BMD 0.78 ± 0.12 0.82 ± 0.17 NS
Trochanter BMD 0.67 ± 0.16 0.69 ± 0.12 NSBMC Gastroenterology 2005, 5:30 http://www.biomedcentral.com/1471-230X/5/30
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patients with chronic hepatitis B and controls were com-
pared using Student's unpaired t test. Results in patients
treated with IFN-alpha alone and combination therapy
were compared using Mann -Whitney -U test. Pearson's
correlation test was used for correlation analysis. All statis-
tical tests were 2-sided; p < 0.05 was considered to be sta-
tistically significant. Values are expressed as the mean ±
standard deviation.
Results
The mean age of patients and healthy control groups were
10.23 ± 3.12 and 10.02 ± 2.84 years, respectively. Patients
group consisted of 43 females and 11 males and there
were 39 females and 11 males in controls group. In both
groups, mean body mass index and other demographic
characteristics were similar. There was no statistically sig-
nificant difference in any demographic characteristics
between the groups (p > 0.05).
There was no statistically significant difference between
patients received recombinant interferon alpha-2b alone
and combination with lamivudine (Table 1).
Laboratory data of both groups are shown in Table 2.
While serum IL-2r (p = 0.002), IL-6 (p = 0.001), IL-8 (p =
0.013), PTH (p = 0.029), and CTX (p = 0.021) levels were
higher in children with chronic hepatitis B than in healthy
controls, there was no significant different in respect to
serum IL-1β, TNF-α and osteocalcin levels. BMD of femur
neck (p = 0.012) and trochanter (p = 0.046) in patients
were higher than in healthy controls.
Correlation between laboratory data and BMD measure-
ments of patients group are shown in Table 3. There was a
statistically significant correlation between serum IL-1β
and osteocalcin (r = -0.355, p < 0.01), ALT (r = 0.494, p =
0.01), and AST (r = 0.528, p = 0.01); between serum IL-8
and CTX levels (r = 0.372, p = 0.01), and ALP (r = 0.361,
p = 0.01); between serum ALP and femur neck BMD (r =
0.303, p = 0.05), and trochanter BMD (r = 0.365, p =
0.01); between spine BMD and IL-2R (r = -0.330, p <
0.05).
Discussion
Osteoporosis is an otherwise healthy child or adolescent
is rare, although cases of idiopathic osteoporosis have
been described. Rather, pediatric osteoporosis is increas-
ingly recognized in the setting of chronic illness related to
the disease itself or its treatment. A large number of stud-
ies on primary osteoporosis have reported recent advances
in research on bone metabolism. However, secondary
osteoporosis has been regarded as a differential diagnosis
of primary osteoporosis, and its pathological mechanisms
have not been elucidated compared with those of primary
osteoporosis [17].
Bone manifestations are well-known extrahepatic compli-
cations of chronic liver diseases [18,19]. In these patients,
several factors contribute to the development of bone dis-
ease. In particular, malnutrition, immobilization, and
hormonal changes are causes for deteriorating bone
metabolism in patients with chronic liver diseases [19].
The mechanism leading to osteoporosis is still unclear.
The equilibrium between bone formation and bone
resorption is disturbed [20], and, apart from the decreased
Table 2: Comparisons of laboratory data and BMD measurements of children with chronic hepatitis B treated with IFN-alpha alone or 
combination with lamivudine and healthy controls.
Variables Patients (n = 54) Control (n = 50) P
TNF-α 25.54 ± 8.30 15.47 ± 6.77 NS
IL-1β 7.32 ± 12.13 5.48 ± 6.14 NS
IL-2r 1403.07 ± 455.67 1120.48 ± 492.37 0.002
IL-6 25.21 ± 39.27 5.98 ± 6.49 0.001
IL-8 18.46 ± 14.77 12.55 ± 7.36 0.013
PTH 41.51 ± 28.80 33.08 ± 18.22 0.029
s-CTX 1.92 ± 0.76 1.61 ± 0.52 0.021
Osteocalcin 64.67 ± 30.63 75.81 ± 31.10 NS
Serum calcium 9.57 ± 1.83 9.49 ± 1.52 NS
ALP 221.27 ± 67.27 219.66 ± 78.74 NS
ALT 62.14 ± 88.31 27.01 ± 42.41 0.009
AST 58.41 ± 65.57 31.72 ± 29.69 0.007
L2–4 BMD 0.62 ± 0.13 0.59 ± 0.12 NS
Femur neck BMD 0.80 ± 0.16 0.72 ± 0.15 0.012
Trochanter BMD 0.68 ± 0.14 0.62 ± 0.14 0.046BMC Gastroenterology 2005, 5:30 http://www.biomedcentral.com/1471-230X/5/30
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activity of osteoblasts [21], there are also studies indicat-
ing an increase in osteoclast activity [22]. In contrast to
primary biliary cirrhosis and primary sclerosing cholangi-
tis, no disease-specific association between chronic hepa-
titis B, C, and D virus infection and osteoporosis is
documented. Only few studies on bone metabolism have
been performed in patients suffering from chronic viral
hepatitis, especially before and after liver transplantation
[23-25].
Bone disease in patients with chronic active hepatitis is
usually asymptomatic and is characterized by decreases in
BMD. Histomorphometric analysis of bone biopsies from
the iliac crest of patients with chronic active hepatitis
shows osteoporosis with decreased trabecular bone vol-
ume and no osteomalacia. Bone remodeling is regulated
by a number of growth factors, cytokines, systemic pep-
tides and steroid hormones. Proinflammatory cytokines
appear to have a role in the development of chronic liver
disease. IL-1b and TNF-alpha are involved in liver fibro-
genesis [26]. The activation of the cytokine cascade,
induces fibroblast proliferation and parenchymal inflam-
matory response producing liver damage [26,27].
The prevalence of osteoporosis among patients with
chronic liver diseases ranges from 10% to 60% [28-31],
the highest being observed in cholestatic liver disease and
alcoholic liver disease. A recent study revealed that the
prevalence of osteoporosis in patients with cirrhosis sec-
ondary to hepatitis B or C was nearly 50% [32]. Most stud-
ies of bone disease were performed in patients with
cirrhosis. Nevertheless, little is known about the occur-
rence of bone disease in non-cirrhotic patients with
chronic hepatitis B or C [33].
Interleukins and lymphokines may play a role in the bone
remodeling process [1]. The calcitonin-like effect of IFN-γ
is difficult to interpret if one assumes that the immune
interferon actually brings about the fusion of monocytes
into osteoclasts. If this actually occurred in bone this
would force the conclusion that these cells can not be acti-
vated in the presence of IFN-γ. This could also explain the
reduced effectivity of PTH in the presence of the immune
interferon. Although IL-1β and TNF-α may be involved in
the bone remodeling process, we did not find any signifi-
cant difference when we compared their serum levels in
children with chronic hepatitis B and healthy controls. It
should be borne in mind that several disputes exist among
researches concerning cytokines and pathologic bone
remodeling, especially concerning the secretion of
cytokines into the peripheral blood. This may be related
to effect of IFN-alpha therapy.
Since biochemical markers of bone turnover are impor-
tant in the assessment of osteoblastic and osteoclastic
functions, we measured the serum osteocalcin and C-ter-
minal cross-linking telopeptide of type I collagen levels.
Osteocalcin is a noncollagenous protein secreted by
osteoblasts and is widely accepted as a marker for osteob-
lastic activity [34] and bone formation [35], whereas
serum CTX, as a collagen-degradation product is a marker
of bone resorption [36].
In some studies, it has been reported that the serum oste-
ocalcin levels are higher in cirrhosis patients, which
means that cirrhotic patients have high turnover oste-
oporosis [37]. However, some authors reported that the
serum osteocalcin levels were lower in cirrhotic patients
and the osteopenia in these patients was not due to a
decrease in bone formation [38,39].




IL-6 .167 -.101 -.163
IL-8 .137 .251 .248 -.126
PTH .005 -.012 .009 .121 .088
s-CTX -.087 -.253 .140 -.060 .372** -.155
ALP -.013 -.049 -.055 -.092 .361** -.102 .179
Osteocalcin .105 -.355** .016 .135 -.205 -.101 .256 -.006
ALT .189 .494** .087 -.161 .243 .122 -.257 .251 -.206
AST .214 .528** .125 -.192 .253 .089 -.222 .252 -.155 .960**
L2–4 BMD -.159 .019 -.330* .036 .138 .226 .122 .072 -.118 .122 .084
Femur Neck BMD -.112 -.043 -.246 .025 .105 .179 .067 .303* -.034 .163 .097 .704**
Trochanter BMD -.111 -.039 -.237 -.006 .123 .090 .017 .365** -.125 .198 .125 .697** .943**
TNF-α IL-1β IL-2r IL-6 IL-8 PTH s-CTX ALP Osteocalcin ALT AST L2–4 BMD Femur Neck BMD
** Correlation is sigificant at the 0.01 level (2-tailed).
* Correlation is significant at the 0.05 level (2-tailed).BMC Gastroenterology 2005, 5:30 http://www.biomedcentral.com/1471-230X/5/30
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In hepatocellular dysfunction, some authors reported that
the serum parathyroid hormone levels were higher [40],
and others reported them as unchanged [29]. Another
report showed that the increase in bone resorption might
be the result of decreased PTH degradation [41]. In our
study, while serum PTH and CTX levels were higher in
children with chronic hepatitis B than in healthy controls,
there was no significant different in respect to serum oste-
ocalcin and ALP levels.
IFN-alpha has numerous clinical applications but is used
most extensively in the treatment of chronic hepatitis B
and chronic hepatitis C. Research into the effects of IFN-
alpha on bone mineral metabolism has been very sparse,
and the majority of studies reflect in vitro models. The
exact mechanism of positive effect on bone mineral
metabolism by IFN-alpha is not completely understood
although a number have been postulated. Both in vivo
and in vitro studies demonstrate that IFN-alpha decreases
bone resorption, whereas osteoblast may or may not be
affected in vivo [42]. An in vitro study on the effects of
IFN-alpha on human bone marrow stromal cells showed
that IFN-alpha decreased the production of IL-1b [43],
which has been shown to stimulate osteoclastic bone
resorption [44].
Takayanagi et al. [45] reported that there is cross-talk
between the tumour necrosis factor and IFN families of
cytokines, through which IFN-gamma provides a negative
link between T-cell activation and bone resorption.
Authors stated that the findings of their study may offer a
therapeutic approach to treat the inflammation-induced
tissue breakdown. IFN-alpha clearly decreases bone
resorption, but in vitro data suggest that there is decreased
formation with increased differentiation of osteoblasts,
whereas the in vivo work suggests that osteoblasts are not
suppressed by IFN-alpha [42]. Thus, IFN-alpha could be
increased BMD in children with chronic hepatitis by one
or a combination of these mechanisms. In our study,
because there is no statistically significant difference
between patients received IFN-alpha alone and combina-
tion therapy we think that changes in BMD biochemical
markers and cytokines are related to IFN-alpha treatment.
Solis-Herruzo et al. [46] reported that adult male patients
receiving ribavirin and IFN-alpha had a lower bone mass
than those receiving IFN-alpha only; this suggests that rib-
avirin was responsible for the decrease in bone mineral
density. This was, however, a cross-sectional study and did
not evaluate patients before treatment, possibly leading to
inconsistent conclusions. Trombetti et al. [47], on the
other hand, did not find any effect of ribavirin in bone
metabolism. The impact, therefore, of IFN-alpha and rib-
avirin in bone remains unclear [48]. In our study, there
was no statistically significant difference between patients
with hepatitis B received IFN-alpha alone and combina-
tion with lamivudine.
In our study, BMD values of femur, but was not spine, in
patients were higher than in healthy controls. High BMD
values of femur postulated that IFN-alpha therapy might
be responsible for inhibiting some mediators. It is further
postulated that these mediators, such as some cytokines,
might be the final common pathway leading to bone loss
in parenchimal liver disorders. Because interferon inhibits
the formation of osteoclast-like cells [49], interferon treat-
ment may increase BMD. However, interferon is expen-
sive and is thus inappropriate for the treatment of bone
lesions. But, it is postulated that in patients treated with
IFN-alpha may not need additional therapy for the treat-
ment of bone resorption.
Conclusion
In conclusion, our study suggest that BMD of femur,
serum IL-2r, IL-6, IL-8, PTH, and CTX levels were higher in
children with chronic hepatitis B treated with IFN-alpha
alone or combination with lamivudine than in healthy
children. High femur BMD measurements found in
patients may suggest that IFN-alpha therapy in children
with chronic hepatitis B could contribute indirectly to pre-
vent from hip osteoporosis. Additionally, further investi-
gations on effects of IFN-alpha for bone structure in
children should be performed in the future.
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